CDK4


Also found in: Acronyms.

CDK4

A gene on chromosome 12q14 that encodes a Ser/Thr kinase, which is the catalytic subunit of the cyclin-dependent protein kinase complex. CDK2 activity is restricted to the G1-S phase, and is controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16(INK4a).

Molecular pathology
CDK4 mutations and those of related proteins (e.g., D-type cyclins, p16(INK4a) and Rb) occur in neoplasia.
References in periodicals archive ?
Cyclin D1 overexpression, together with other positive cell cycle regulators such as cyclin E, cdk4, cdkn2a, cdkn2b, and PCNA was evident in arsenic-exposed tissues in the present study.
Percentage of BrdU positive cells as well as expression levels of cyclinD1, CDK6, CDK4, and VEGF was significantly reduced by either LY294002 or SP600125 relative to the LIPUS group (P<0.05 or P< 0.01, Figure 5A and B).
Thway et al (27) examined IHC staining with p16, MDM2, and CDK4 in 216 adipocytic neoplasms, which included 31 ALT/WDL and 57 DDL.
When these proliferative SCs were transfected with a recombinant lentivirus expressing miR-let-7b, cyclin D1 and CDK4 levels were reduced and cell proliferation was halted [56].
(a) The expression of p16, CDK4, CDK6, cyclin D1, pRb, and E2F1 was detected by Western blot analysis.
Explant-induced reactivation of herpes simplex virus occurs in neurons expressing nuclear cdk2 and cdk4. J Virol 2002; 76:7724-35.
There was scattered nuclear MDM2 immunoreactivity within several cells (Figure 1(e)), whilst a CDK4 immunostain was negative (data not shown).
Real-time RT-PCR demonstrated that the expression of the cell cycle-driving molecule, cyclin-dependent kinase 4 (Cdk4), in HCC was significantly reduced by the treatments with vitamin K2, K3 and K5.
Writing in the journal Cancer Cell, they said the overproduction of the common protein cyclin D1 hyperstimulated the growth switch CDK4 kinase in the body.
A French study exploring genetic risk factors for melanoma also named CDKN2A as a target gene for susceptibility, along with CDK4 (Biochimie 84[1]:67-74, 2002).
AroCell initiated a collaboration with the Dana Farber Cancer Institute to evaluate AroCell TK 210 ELISA on patients treated with CDK4 / 6 inhibitors.